EP4620526A2 — Pharmaceutical combination comprising ponesimod and its use in the treatment of multiple sclerosis
Assigned to Laboratoires Juvise Pharmaceuticals SAS · Expires 2025-09-24 · 1y expired
What this patent protects
The present invention relates to a pharmaceutical combination comprising a first active ingredient which is (R)-5-[3- chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4- one or a pharmaceutically acceptable salt thereof and a second activ…
USPTO Abstract
The present invention relates to a pharmaceutical combination comprising a first active ingredient which is (R)-5-[3- chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4- one or a pharmaceutically acceptable salt thereof and a second active ingredient which is selected from the group consisting of methyl fumarate, dimethyl fumarate, (N,N- diethylcarbamoyl)methyl methyl (2E)but-2-ene-1 ,4-dioate, and 2-(2,5-dioxopyrrolidin-1-yl)ethyl methyl (2E)but-2-ene-1 ,4-dioate, or a pharmaceutically acceptable salt thereof.
Drugs covered by this patent
- Tecfidera (DIMETHYL FUMARATE) · Biogen
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.